Citi analyst Mohit Bansal reiterated a Buy rating and $150.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).

• Analyst is buyer on weakness.
• Sees FV around $131 to $133 per share.
• Says while weakness is justified, there is still value in the equity.

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $112.17 yesterday.

Analyst Comments Hot Comments

Stifel Reiterates Hold Rating on Alexion Pharmaceuticals (ALXN)August 30, 2019 12:14 PM Alexion (ALXN) Soliris IPR Surprising, But Long-Term Impact 'Limited' - Raymond JamesAugust 30, 2019 10:59 AM Piper Jaffray Defends Alexion Pharmaceuticals (ALXN)August 30, 2019 10:44 AM Alexion Pharmaceuticals (ALXN) PTAB News an 'Incremental Negative' - BairdAugust 30, 2019 10:25 AM Increasing unusual option volume: ALXN COO ULTA DELL AMBA August 30, 2019 10:04 AM Pre-Open 08/30: (SEAC) (AMBA) (MSGN) Higher (ULTA) (AOBC) (ALXN) Lower (more...)August 30, 2019 9:19 AM Alexion Pharma (ALXN) Soliris patents get review on Amgen (AMGN) challenge at patent office - BloombergAugust 30, 2019 8:49 AM Alexion Announces Upcoming Data Presentations at 35th Congress of the European Committee for Treatment and Research in Multiple SclerosisAugust 28, 2019 8:30 AM Alexion to Present at the 14th Annual Citi Biotech ConferenceAugust 28, 2019 6:30 AM